Clonidine

Basic Clonidine Information

• INN (International Nonproprietary Name): Clonidine (also recognised as Clonidinum, Clonidina, Clonidin).
• Brand Names Available In United Kingdom: Catapres and Catapres‑TTS are listed for the UK; Kapvay and other brands appear in some jurisdictions but check local NHS formularies for availability.
• ATC Code: C02AC01 (Antihypertensives, Imidazoline Derivatives).
• Forms & Dosages: Tablets 0.1 mg, 0.15 mg, 0.2 mg, 0.3 mg; Extended‑release tablets 0.1 mg, 0.2 mg; Transdermal patches 0.1 mg, 0.2 mg, 0.3 mg/24 h; Injection 100 mcg/mL and 500 mcg/mL; eye drops in select markets 0.1%.
• Manufacturers In United Kingdom: Major global suppliers include Pfizer, Boehringer Ingelheim, Sandoz (Novartis), Mylan and Teva; generic suppliers are widely available and local wholesalers may supply branded Catapres or generic clonidine.
• Registration Status In United Kingdom: Clonidine (Catapres formulations) is registered for hypertension and available in the UK market; check the product licence (SmPC) and local NHS guidance for specific formulations and indications.
• OTC / Rx Classification: Prescription Only Medicine (POM) in the UK and in most major markets.

Critical Warnings & Restrictions

High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)

Clonidine can cause marked sedation, hypotension and bradycardia, which are clinically significant risks for vulnerable patients.

Absolute contraindications include hypersensitivity to clonidine and severe bradyarrhythmia or advanced AV block in patients without a pacemaker.

Relative concerns include renal impairment, significant coronary artery disease, severe hepatic impairment and a history of depression, all of which need closer monitoring and dose adjustment.

Pregnancy requires specialist review because risks and benefits vary; maternal blood‑pressure control and foetal safety must be weighed using local guidance.

Breastfeeding mothers need individual assessment because clonidine passes into breast milk and may sedate the infant.

Elderly patients should start at lower doses, for example 0.05 mg twice daily, and be titrated slowly with home blood‑pressure monitoring to reduce falls and orthostatic events.

Use this pre‑treatment checklist before initiation.

• Baseline blood pressure and heart rate measurement.
• ECG if there is a history or suspicion of bradyarrhythmia or conduction disease.
• Renal and liver function tests where indicated.
• Full medication reconciliation to identify additive effects with other CNS depressants or antihypertensives.
• Falls risk assessment, especially in older adults and those with balance problems.

Interaction With Activities (Driving, Workplace Safety Under UK Law)

Clonidine commonly causes sedation and dizziness, which can impair driving and the safe use of machinery.

Under UK rules patients must ensure they are fit to drive and must not drive if their concentration, alertness or coordination are affected.

If clonidine affects driving ability the patient should discuss dose timing or alternatives with their GP or pharmacist and may need to inform the DVLA.

Q&A — “Can I Drive After Taking It In The UK?”

There is no guarantee you can drive safely after taking clonidine; if you feel drowsy, dizzy or less alert do not drive.

UK guidance requires drivers to remain safe; inform the DVLA if treatment affects concentration or alertness as this can affect driving licence duties.

Discuss timing of doses with your GP or pharmacist — taking the main dose at night can reduce daytime sleepiness for some patients.

Usage Basics

INN, Brand Names Available In The UK

The International Nonproprietary Name is clonidine.

In UK practice the common brands are Catapres tablets and Catapres‑TTS transdermal patches, plus generic clonidine tablets from various suppliers.

Kapvay (extended‑release) is available in some jurisdictions and is used mainly for paediatric ADHD; confirm local NHS formularies for availability and preferred preparations.

Legal Classification (POM, P, GSL)

Clonidine is a Prescription‑Only Medicine (POM) in the UK and is regulated by the MHRA.

It is dispensed via NHS prescriptions or private prescriptions, and electronic prescribing is commonly used in general practice.

Dosing Guide

Standard Regimens (NHS Guidelines)

For adults with hypertension, oral initiation is typically 0.1 mg twice daily with titration by 0.1 mg every 1–2 weeks up to clinical response; maximum reported doses reach 2.4 mg/day.

For ADHD using paediatric extended‑release formulations, initiation is often 0.1 mg at night with weekly increments as tolerated.

In acute opioid or alcohol withdrawal settings short regimens use 0.1–0.2 mg every 4–6 hours to control autonomic symptoms, under supervision.

Epidural or injectable clonidine is used in specialist pain management, for example a continuous infusion started around 30 mcg/hr and titrated to effect in a specialist setting.

Adjustments For Comorbidities

Children start low for ADHD, commonly 0.05–0.1 mg at night, and dose is adjusted by response while avoiding abrupt cessation.

Elderly patients should begin at lower doses such as 0.05 mg twice daily with slow titration and monitoring for orthostatic hypotension.

In renal impairment dose reductions are advised because clonidine is partly renally excreted and CNS depression risk increases.

In hepatic impairment use clonidine with caution and monitor clinically due to hepatic metabolism.

Q&A — “What If I Miss A Dose?”

If you miss a tablet dose, take it as soon as you remember unless your next dose is near, in which case skip the missed dose.

Do not double up doses to make up for a missed tablet.

For patches replace the patch at the scheduled time; if a patch falls off contact your prescriber or pharmacist for advice and do not reapply a partially used patch without guidance.

• Titration Steps: Start 0.1 mg BID for adults, increase by 0.1 mg every 1–2 weeks to response; elderly start 0.05 mg BID and titrate slowly.
• Monitoring Checklist: Regular BP/HR checks during titration, watch for sedation, assess falls risk and record any skin reactions with patches.

Interaction Chart

Food And Drinks (Alcohol, Tea/Coffee, Diet Habits)

Alcohol potentiates central nervous system depression and hypotension with clonidine, so advise patients to avoid or limit alcohol while taking the medicine.

Caffeine may mask some sedative effects but does not prevent hypotension and is not a substitute for monitoring symptoms.

No major food–drug interactions are recorded, but maintain consistent meal patterns to reduce orthostatic symptoms when standing up.

Common Drug Conflicts (MHRA Yellow Card Data)

Use extra caution with other antihypertensives due to additive hypotensive effects.

Beta‑blockers and calcium‑channel blockers may increase risk of bradycardia and conduction abnormalities when combined with clonidine.

Sedative medicines including hypnotics and opioids can increase sedation and respiratory depression risk when used together with clonidine.

Tricyclic antidepressants and MAO inhibitors have complex interactions and warrant specialist advice.

Abrupt withdrawal of clonidine can interact with other agents by provoking a sympathetic surge and rebound hypertension.

• Drugs Needing Extra Monitoring: Beta‑blockers, methyldopa, guanfacine and other central agents.

User Reports & Trends

Patients commonly search for terms such as “Clonidine Catapres 0.15mg”, “clonidine for opioid withdrawal” and “clonidine for ADHD”.

Online patient discussions on NHS.uk, Patient.info, Mumsnet and forums report frequent side effects including dry mouth, drowsiness, dizziness and constipation.

Transdermal patches are often praised for adherence benefits in elderly patients who struggle to swallow tablets, though patch adhesion and local skin irritation are commonly reported negatives.

Many users report clonidine helps reduce autonomic symptoms in withdrawal, but emphasise the need for supervised detox and multimodal care.

Tolerability

Dry mouth, drowsiness and mild hypotension predominate.

Efficacy

Good antihypertensive effect for central action; symptomatic relief in withdrawal reported anecdotally.

Adherence

Patches improve adherence in patients with swallowing difficulties.

Patch Issues

Local erythema, pruritus and occasional detachment.

Forum and anecdotal data are not a substitute for clinical advice; advise patients to consult NHS resources or a pharmacist for personalised guidance and to report adverse reactions via the MHRA Yellow Card.

• Typical Patient Concerns To Surface In Consultations: daytime sleepiness, constipation, symptomatic hypotension and patch adhesion.

Access & Purchase Options

Boots, LloydsPharmacy, Superdrug

High‑street community pharmacies including Boots, LloydsPharmacy, Superdrug and independent pharmacies dispense clonidine on NHS or private prescription and provide counselling on dosing and side effects.

Community pharmacists can order brand or generic supplies if a particular formulation is preferred by the prescriber or patient.

Online Pharmacies And NHS E‑Prescriptions

Electronic prescriptions via the NHS e‑prescribing system are common and patients can nominate a pharmacy to collect their medication.

Several MHRA‑registered online pharmacies can dispense clonidine on receipt of an electronic or postal GP prescription; always verify GPhC registration before purchase.

Checklist For Patients Before Ordering:

• Check prescription validity and that the pharmacy is GPhC registered.
• Confirm the correct formulation (tablet vs patch) and strength with the prescriber.
• Confirm cost and any NHS exemptions or entitlement.

In our online pharmacy, clonidine is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Mechanism & Pharmacology

Simplified Explanation

Clonidine is a centrally acting alpha‑2 adrenergic agonist that reduces sympathetic outflow from the brainstem, lowering peripheral vascular resistance and heart rate.

This mechanism reduces blood pressure and attenuates the sympathetic overactivity seen in opioid or alcohol withdrawal.

Clonidine also acts at imidazoline receptors, which contributes to its antihypertensive effects and explains its ATC classification C02AC01.

Clinical Terms

Oral tablets and extended‑release formulations have differing absorption profiles, while transdermal patches deliver steady plasma levels over 24 hours for more constant effect.

Injectable clonidine yields an immediate effect and is used in specialist acute or epidural settings.

Clonidine undergoes hepatic metabolism with partial renal excretion, so dose adjustments are required in renal impairment and caution is advised in hepatic disease.

Alpha‑2 Agonist

An agent that reduces sympathetic tone via central alpha‑2 receptors.

Imidazoline Receptor

A receptor subtype implicated in central blood‑pressure regulation.

Transdermal Patch Kinetics

Provides steady plasma concentration over 24 hours, improving adherence.

Extended‑Release Tablet

Designed for sustained plasma levels and once‑daily dosing in some indications.

Indications & Off‑Label Uses

MHRA‑Approved Uses

Regulatory registrations list hypertension as the primary indication for clonidine formulations.

Clonidine formulations are also used in ADHD and specialist pain management in some jurisdictions, and prescribers must follow MHRA and local NHS formularies for licensed indications.

Off‑Label Practices In NHS And Private Care

Common off‑label uses in UK practice include management of opioid and alcohol withdrawal symptoms and adjunctive low‑dose use for migraine prophylaxis.

Specialist pain clinics use epidural or intrathecal clonidine as part of multimodal analgesia.

Off‑label use should be documented with informed consent and a clear rationale recorded in the clinical notes.

• Prescriber Checklist: state the indication, summarise the evidence, list alternative options, obtain informed consent, set a monitoring plan and report adverse events appropriately.

Dosing Examples For Indications:

• Hypertension (Adults): Start 0.1 mg twice daily, titrate by 0.1 mg every 1–2 weeks to response.
• ADHD (Paediatric ER): Start 0.1 mg at night, increase weekly as tolerated.
• Withdrawal Support: 0.1–0.2 mg every 4–6 hours in supervised settings.
• Epidural Analgesia: Specialist infusions starting around 30 mcg/hr and titrating to effect.

Key Clinical Findings

Regulatory approvals and guideline summaries show clonidine is an effective centrally acting antihypertensive agent and has recognised uses in ADHD and certain pain settings.

Systematic reviews and national guidance position clonidine as a second‑ or third‑line centrally acting antihypertensive in many algorithms and as an adjunct in selected neuropsychiatric indications.

For withdrawal management, evidence supports symptomatic relief of autonomic symptoms though complete detoxification requires multidisciplinary care.

• Key Safety Signals From Recent Surveillance: sedation, hypotension, skin reactions to patches and rebound hypertension if stopped abruptly.

Clinicians should consult NICE guidance, the SmPC and up‑to‑date systematic reviews from 2022–2025 when making treatment decisions.

Alternatives Matrix

NHS Prescribing Alternatives (Comparison Table)

Pros And Cons Checklist

Pros Of Clonidine: effective central antihypertensive mechanism, transdermal option improves adherence in some patients, useful in withdrawal symptom control.

Cons Of Clonidine: sedation is common, risk of rebound hypertension on abrupt cessation, renal dose adjustments required and skin reactions with patches.

• Patient Scenarios Favouring Clonidine: need for a transdermal delivery route, intolerance to ACE inhibitors, symptomatic autonomic withdrawal control under supervision.

Common Questions

Will clonidine make me sleepy all day?

Daytime sedation is common; consider night dosing or slow titration and discuss with your GP or pharmacist before driving.

Can I stop clonidine suddenly?

No; abrupt discontinuation can provoke rebound hypertension and a sympathetic surge, so taper slowly under clinician supervision.

Are patches better than tablets?

Patches improve adherence and steady plasma levels but may cause local skin reactions and are usually costlier; choice depends on clinical need and patient preference.

Is clonidine safe in pregnancy?

Pregnancy requires specialist input and alternatives are often preferred; document risks and benefits clearly when prescribing.

• When To Call GP/999: syncope, severe bradycardia, breathing difficulties or signs of severe allergic reaction.
• When To Report Side Effects: report via the MHRA Yellow Card scheme for suspected adverse reactions.

NHS Cost & Access Comparison Table

Use the table below as a template; confirm live prices with the pharmacy before publication.

Regional Differences Summary: In England a standard prescription charge applies per item unless a patient is exempt or holds a Prescription Prepayment Certificate.

In Scotland, Wales and Northern Ireland prescriptions are generally free for residents.

Checklist For Patients: confirm current prescription charge at NHS.uk, consider a Prescription Prepayment Certificate if you take multiple medicines and check if you qualify for exemption based on age or benefits.

Registration & Regulation

MHRA Approval Process

Clonidine products on the UK market are authorised via MHRA or EU/EMA routes and clinicians should consult the product licence (SmPC) for licensed indications, contraindications and monitoring requirements.

Adverse reactions should be reported through the MHRA Yellow Card scheme to support post‑marketing surveillance.

NHS Prescribing Framework

Prescribing clonidine on the NHS follows local formulary guidance and any applicable NICE recommendations.

Electronic prescriptions and repeat prescribing must include a monitoring plan for blood pressure and heart rate, clear titration and stopping instructions.

• Prescriber Checklist: check the SmPC, document indication, record consent for off‑label use, specify monitoring intervals, list interactions and warn about withdrawal risks.
• Reporting Routes: MHRA Yellow Card for adverse events and local governance for formulary exceptions.

Storage & Handling

UK Household Storage (Cold/Damp Climate)

Tablets should be stored at room temperature, protected from moisture, typically 15–30°C.

Given the UK’s variable humidity avoid storing tablets in bathrooms or near sinks where moisture can degrade the product.

Keep all medicines out of reach of children and pets and in original packaging to avoid confusion.

Guidance From NHS And Pharmacists

Patches should be stored flat in their sealed packaging and kept away from direct sunlight and heat sources.

Do not use external heat sources such as heated blankets or heating pads over patch application sites as heat can increase systemic absorption.

Discard used patches safely by folding the adhesive sides together and disposing of them according to local guidance to prevent accidental exposure to children or pets.

• Patient Checklist: rotate application sites, clean and dry the skin before applying a patch, what to do if a patch peels off, safe disposal and when to seek medical advice for skin reactions or systemic symptoms.

Travel Advice: carry medication in original packaging with prescription details, keep patches flat and avoid extreme temperatures during flights or in checked luggage.

Guidelines For Proper Use

UK Pharmacist Counselling Style

Adopt a safety‑first counselling approach: confirm the indication and explain how to take tablets and apply patches correctly.

Warn about possible sedation and the impact on driving, advise on alcohol avoidance and explain the risk of rebound hypertension on abrupt cessation.

Provide clear monitoring advice for BP and heart rate and give written information signposting to NHS.uk or Patient.info leaflets.

NHS Patient Safety Advice

Practical safety checklist for patients includes carrying a list of medications, measuring blood pressure regularly during titration and avoiding sudden stopping without advice.

Report severe dizziness, syncope, breathing difficulties or very low heart rate to the GP or emergency services immediately.

For children on ADHD regimens liaise with the school about dosing times, watch for changes in sleep and appetite and discuss dose timing with the prescriber.

• Short Handout: when to contact GP, when to attend A&E, how to report side effects via the Yellow Card and how to contact the pharmacy for minor queries.

Delivery Across United Kingdom

Final Notes

Clonidine is a useful centrally acting medicine with multiple formulations and clinical roles, but it requires careful patient selection and monitoring because of sedation, hypotension and withdrawal risks.

Pharmacists should ensure patients receive clear verbal and written advice about dosing, driving, alcohol and how to report adverse effects via the MHRA Yellow Card.

Always consult the SmPC for the specific product being supplied and document off‑label use, monitoring plans and consent where appropriate.